Clinical Trial

A Study of Ruxolitinib in Patients With Graft-Versus Host Disease

Recruiting
View on ClinicalTrials.gov →
Summary
This study aims to evaluate the safety and effectiveness of Jakavi® (ruxolitinib) in patients with acute graft-versus host disease (GVHD) and chronic GVHD in clinical practice.
Protocol Amendment History 3 changes
critical Recruitment opened 2026-06-09
notable Primary completion pushed: 2030-03-15 -> 2030-05-15 2026-06-09
minor Completion pushed: 2030-03-15 -> 2030-05-15 2026-06-09
Trial Details
NCT Number NCT07594587
Lead Sponsor Novartis Pharmaceuticals
Conditions Graft-Versus-Host Disease
Enrollment 395 participants
Start Date 2026-05-11
Primary Completion 2030-05-15 (estimated)
Study Completion 2030-05-15 (estimated)
Updated on ClinicalTrials.gov 2026-06-08